Overview

A Study of High-Risk Oral Cavity Cancer

Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Objectives: 1. To study the effect of anti-angiogenesis therapy on reducing the recurrence of high-risk oral cavity cancer patients after curative local treatment. 2. To study the toxicity and compliance of post-operative anti-angiogenesis therapy Study design: This is a multi-center randomized controlled phase II/III two-stage study. Study endpoints: The primary endpoint is the tumor-free survival (primary and second primary malignancies) and the primary analysis is to compare the tumor-free survival between groups.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Buddhist Tzu Chi General Hospital
Chang Gung Memorial Hospital
Changhua Christian Hospital
Chi Mei Medical Hospital
Kaohsiung Veterans General Hospital.
Mackay Memorial Hospital
National Cheng-Kung University Hospital
National Taiwan University Hospital
Sun Yat-sen University
Treatments:
BB 1101
Celecoxib
Cyclophosphamide
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Thalidomide